Shenzhen Efung Capital, one of the earliest VC/PE companies in China, focuses on the investment of biopharmaceutical and medical device companies. Efung has invested about 20 new drug and medical device companies in China and internationally. Of which, Chipscreen (Shenzhen) marketed an anti-cancer new drug, Chidamide, in 2015; Frontier Biotech（Nanjing）will market Albuvirtide within months, which could become one of the world's first long-acting anti-HIV new drug ever approved; Ascentage Pharma (Jiangsu) and Gmax Biopharm (Hangzhou) will be IPO in NASDAQ in 2018. Since 2015, Efung initiated two U.S. Dollar Fundings and already invested 5 Pharmaceutical companies, such as Aridis, Reservlogix, Centrexion, et.al. We collaborate with many individual and institution investors, public listed pharmaceutical/medical device companies, investing banks and governmental agents from China, and internationally.
From the publishers of Nature, the BioPharma Dealmakers website brings together life sciences companies and individuals looking to identify and attract partners and dealmaking opportunities. It provides insights into dealmaking trends from BioPharma Dealmakers Editors, profiles from companies looking to partner, tools for networking and sharing knowledge, and the opportunity for sponsoring companies to showcase their expertise. BioPharma Dealmakers is THE destination for partnering professionals looking to make connections and get the latest on their industry.